&w=3840&q=100)
Eli Lilly's tirzepatide shows superior weight loss to Novo's semaglutide
US-based pharmaceutical company Eli Lilly has announced results from a head-to-head clinical trial showing that its obesity drug tirzepatide (sold as Mounjaro) led to greater weight loss in adults than semaglutide (sold as Wegovy).
The detailed findings from the 72-week phase 3b SURMOUNT-5 trial were presented at the European Congress on Obesity and published in The New England Journal of Medicine.
Participants using tirzepatide lost an average of 20.2 per cent of their body weight, or 22.8 kg, compared to 13.7 per cent, or 15.0 kg, with semaglutide. The trial included 751 adults with obesity or overweight with weight-related health conditions, but without diabetes.
Tirzepatide also performed better on all secondary goals. Nearly 65 per cent of participants taking tirzepatide lost at least 15 per cent of their body weight, compared to 40 per cent on semaglutide. In terms of waist circumference, the average reduction was 18.4 cm with tirzepatide and 13.0 cm with semaglutide.
The trial was not designed to directly compare the safety profiles of the two drugs. However, gastrointestinal issues were the most common side effects in both groups. About 6.1 per cent of participants on tirzepatide stopped treatment due to side effects, compared to 8.0 per cent on semaglutide.
In India, Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes, and is positioning it for use in obesity care as well. 'The results from SURMOUNT-5 provide evidence for tirzepatide as a treatment option for obesity in India,' said Winselow Tucker, President and GM, Eli Lilly India.
Both medications are part of a newer class of drugs that act on hormone receptors involved in appetite regulation. Tirzepatide targets two receptors (GIP and GLP-1), while semaglutide targets only one (GLP-1). Participants in the study were also advised on a reduced-calorie diet and physical activity.
Eli Lilly's tirzepatide is sold as Zepbound in the US for obesity, and as Mounjaro for type 2 diabetes. Semaglutide is marketed by Novo Nordisk under Wegovy for obesity and Ozempic for type 2 diabetes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 hours ago
- The Hindu
Advent to invest $175 million in Felix Pharma to acquire minority stake
Advent, a private equity investor, has announced that funds managed by it have signed a definitive agreement to invest $175 million via primary and secondary capital for a significant minority stake in Dublin, Ireland-based Felix Pharmaceuticals Pvt. Ltd. (Felix), a global Gx animal pharma player. Felix Pharma is one of the developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the U.S. Shweta Jalan, Managing Partner, Advent, said, 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx. Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities.' 'Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' she added, Founded in 2015 by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, Chair of GSK and with 30 years of experience in global pharmaceuticals, and Dr. Shumeet Banerji, ex-CEO of Booz-Allen, Felix said it has pursued strategic growth through a disciplined approach, While the company achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline. It has a USFDA-approved oral solid facility dedicated to animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder, Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger. Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence.'
Indian Express
3 hours ago
- Indian Express
Ahmedabad reports highest single-day rise in Covid cases; state's active case tally at 1,109
With 131 new cases of Covid in Ahmedabad — the highest single-day rise in the city — the state recorded 235 new cases on Monday. Ahmedabad Municipal Corporation's (AMC's) health officials confirmed that Monday's was the highest number of Covid cases that the city has reported in 24 hours after the fresh spate of cases. The total number of active cases in the state stands at 1,109, including 33 people who needed hospitalisation. Others are undergoing OPD-based treatment. Another 106 people, who recovered from the virus, were discharged on Monday. As per a health bulletin released by the state government, no death was reported in Gujarat on Monday. In Ahmedabad, the tally of cases has gone up to 916, including 646 active. Ahmedabad city has reported two deaths due to Covid. Among the active cases in Ahmedabad, highest were reported in the the west zone at 211, followed by the north west zone at 204, and south west zone at 114. The remaining zones have reported 50 (south zone), 25 (north zone), 24 (east zone), 18 (central zone) cases. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), the XFG variant of the Covid-19 has been recently found in a total of 163 samples — with the highest (89) in Maharashtra, followed by Tamil Nadu (16), Kerala (15), Gujarat (11), and Andhra Pradesh, Madhya Pradesh and West Bengal (6 each). The recombinant XFG variant harbours four key spike mutations and has achieved rapid global spread following its initial detection in Canada, according to an article in The Lancet journal. In May, as many as 159 samples were detected with XFG variant, two in April, and two in June yet, data shows. India's active Covid case tally crossed the 6,000 mark, with 769 having been added to it in 48 hours, according to Union Health Ministry data released on Sunday
Time of India
5 hours ago
- Time of India
Luxury skincare expansion: L'Oreal acquires majority stake in Medik8; announces 1 billion Euro deal
Cosmetics maker L'Oreal agreed to acquire a majority stake in British skincare brand Medik8, in a strategic move to strengthen its presence in the booming skincare market. The French beauty giant announced the deal on Monday, though financial terms were not disclosed. The transaction, which sees UK-based private equity firm Inflexion selling its majority holding, reportedly values Medik8 at around 1 billion Euro, according to a source familiar with the matter. Inflexion will retain a minority share, while L'Oreal has secured the option to eventually buy out all remaining shareholders, Reuters reported. 'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' Cyril Chaupuy, president of L'oreal Luxe said. 'This acquisition further strengthens L'Oreal's luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth,' the company said in a statement. L'Oreal will begin consolidating Medik8's sales once the transaction officially closes. The acquisition is expected to be finalised in the coming months, pending regulatory approvals and standard closing conditions. Simon Coble, CEO of Medik8 also expressed excitement on the brand's behalf. 'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.' Founded in the UK, Medik8 has built a loyal customer base with its vitamin A-focused anti-ageing creams and serums. The brand is seen as a natural fit for L'Oreal's luxury division, which includes skincare and fragrance names such as Lancome, Aesop, and Miu Miu. Last year, sales in L'Oreal's luxe segment grew by just 2.7%, its weakest performance across divisions, as inflation pushed consumers toward more affordable alternatives. However, the unit scrored better than rival LVMH's beauty arm. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
